IPSWICH, Mass., Feb. 27, 2019 /PRNewswire/ -- At this year's Advances in Genome Biology and Technology (AGBT) General Meeting, NEB scientists and collaborators will present a broad range of sample preparation technologies, as well as basic research findings, that address issues in various next generation sequencing areas.
One highlight will be NEB's new NEBNext Enzymatic Methyl-seq Kit (EM-seq™), an alternative to bisulfite sequencing for methylome analysis. Several presentations and posters will describe this novel enzyme-based technology that offers unmatched performance, including superior sensitivity of detection of 5-mC and 5-hmC and uniformity of GC coverage.
This year's meeting will be held from February 27th – March 2nd in Marco Island, Florida. During the conference, NEB will be based in the Osprey 3 Suite. Below is a preview of activities during the conference:
Presentations:
Advances in Genome-wide | Jennifer Ishii, The New York Genome Center
Friday's Bronze Sponsor Workshop
|
ReCappable-seq and Nanopore | Laurence Ettwiller, New England Biolabs, Inc.
Thursday's Poster Flash Talk Session
|
Deciphering the Methylome: | Louise Williams, and Chaithanya Ponnaluri, New England Biolabs, Inc.
Osprey 3. Thursday, February 28th, 8:00 – 8:30 AM
|
Shifting the Paradigm for Targeted | Andrew Barry, New England Biolabs, Inc.
Osprey 3. Friday, March 1st, 8:00 – 8:30 AM
|
A number of posters will be presented during the conference (see list below) and also displayed in Osprey 3. There will be several opportunities to meet with our Research and Development Scientists and learn more about topics including the following:
An enzymatic alternative to bisulfite sequencing with superior performance: The upcoming NEBNext Enzymatic Methyl-seq (EM-seq™) products provide an enzymatic alternative to bisulfite sequencing, combined with high-efficiency, streamlined library preparation. This new technology conveys multiple advantages, and enables detection of more CpGs with fewer sequence reads.
NEBNext Companion Module for Oxford Nanopore Technologies Ligation Sequencing: Available soon, this will include the NEBNext DNA repair, End prep and Ligation reagents recommended for use alongside Oxford Nanopore Technologies SQK-LSK109 on their sequencing platforms, at volumes tailored for this workflow, simplifying the ordering process and reducing waste.
RNA depletion: NEB will preview new options for depletion of abundant RNAs, including globin and bacterial samples, as well as a custom solution.
NEBNext Direct® Custom Ready Panels: Easy and rapid customization of NEBNext Direct target enrichment technology is now possible. Custom panels can be designed from a list of 850 genes, sequence-verified and received within two weeks.
Conference posters:
Selective Removal of Abundant RNAs | Deyra Rodriguez, New England Biolabs, Inc, |
| Vladimir Potapov, New England Biolabs, Inc,
|
ReCappable-seq and Nanopore
|
New England Biolabs, Inc,
Note: This is also a Featured Poster
|
An evening with NEBNext scientists
NEB will also host a "NEBNext Soiree" cocktail event to provide conference attendees an opportunity to engage with NEBNext scientists, as well as a chance to win raffle prizes, on Thursday, February 28th at 9:30 pm in the Osprey 3 Suite.
A full summary of NEB's activities at the 2019 AGBT conference, can be found here
For more information on the NEBNext portfolio of reagents for sample preparation, visit www.NEBNext.com
About New England Biolabs
Established in the mid 1970's, New England Biolabs, Inc. (NEB) is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including molecular diagnostics development. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and seven subsidiaries located in Canada, China, France, Germany, Japan, Singapore and the UK. For more information about New England Biolabs visit www.neb.com.
NEB®, NEW ENGLAND BIOLABS®, NEBNEXT® and NEBNEXT DIRECT® are registered trademarks of New England Biolabs, Inc. ULTRA™ is a trademark of New England Biolabs, Inc. OXFORD NANOPORE TECHNOLOGIES® is a registered trademark of Oxford Nanopore Technologies, Inc.
SOURCE New England Biolabs
